Clinical characteristics of chemotherapy-induced alopecia in childhood - 14/02/14
Abstract |
Background |
Chemotherapy-induced alopecia (CIA) is a frequent complication in patients with cancer. There are an increasing number of reports of permanent CIA.
Objective |
We investigated the clinical characteristics of CIA, including permanent CIA in childhood.
Methods |
We collected data on 159 pediatric patients who had undergone high-dose conditioning chemotherapy followed by hematopoietic stem cell transplantation and 167 control subjects, using a questionnaire, medical record reviews, and phototrichograms.
Results |
Alopecia began at 1.5 ± 1.4 months and was sustained until 2.2 ± 1.6 months after chemotherapy initiation. Hair regrowth started 2.6 ± 1.6 months after chemotherapy ceased and lasted for 7.3 ± 4.9 months. The mean hair density and thickness were 198.3 ± 47.4/cm2 and 76.3 ± 18.4 μm in the patient group and 229.6 ± 34.5/cm2 and 79.5 ± 12.4 μm in the control group, respectively (both, P < .001). In all, 19 (12%) patients experienced permanent CIA. Thiotepa use was identified as a significant risk factor for permanent CIA (odds ratio 7.57, P = .002).
Limitations |
Cross-sectional study in a single-center is a limitation.
Conclusion |
CIA is common in pediatric patients. Use of thiotepa is strongly associated with permanent CIA.
Le texte complet de cet article est disponible en PDF.Key words : alopecia, chemotherapy, chemotherapy-induced alopecia, childhood, hematopoietic stem cell transplantation, permanent, thiotepa
Abbreviations used : CI, CIA, GPA, HD, HSCT, HT
Plan
Drs Kwon and Kang contributed equally to this work. |
|
Supported in part by a grant (No. 2012R1A1A2005302) from the Basic Science Research Program through the National Research Foundation of Korea, funded by the Ministry of Education, Science, and Technology; and by the Research Resettlement Fund for new faculty of Seoul National University (No. 800-20120405). |
|
Conflicts of interest: None declared. |
Vol 70 - N° 3
P. 499-505 - mars 2014 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?